Calcium channel blocker reduces adverse cardiovascular events in certai...( The calcium channel blocker amlodipine ...),Health

The calcium channel blocker amlodipine decreases the risk of cardiovascular events (such as heart attack or heart-disease related deaths) in patients with coronary artery disease and normal blood pressure, as does the ACE inhibitor enalapril, but to a lesser extent, according to a study in the November 10 issue of JAMA.

Despite more than 30 years of clinical trials, uncertainty has existed regarding the optimal use of antihypertensive drugs in patients with coronary artery disease (CAD), according to background information in the article.

Steven E. Nissen, M.D., of the Cleveland Clinic Lerner School of Medicine, Cleveland, and colleagues examined the effects of antihypertensive drugs in 1,991 patients with CAD and normal blood pressure in the Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT) study, a double-blind, randomized, multicenter 24-month trial (enrollment April 1999-April 2002). Patients received either the calcium channel blocker amlodipine (10 mg); the angiotensin-converting enzyme (ACE) inhibitor enalapril (20 mg); or placebo. In addition, a subset of 274 patients underwent serial intravascular ultrasound (IVUS) examinations to determine if either or both medications reduced the progression of atherosclerosis.

The primary end point was the time to first occurrence of an adverse cardiovascular event such as cardiovascular death, nonfatal heart attack, coronary revascularization, hospitalization for angina pectoris, hospitalization for congestive heart failure, fatal or nonfatal stroke, or diagnosis of vascular disease.

The researchers found that for patients with a baseline systolic blood pressure averaging only 129/78 mm Hg, amlodipine reduced blood pressure an average of 5/3 mm Hg and compared to placebo, produced a 31 percent relative reduction (6.5 percent absolute reduction; 23.1 percent event-rate for placebo, 16.6 percent event rate for amlodipine) in cardiovascular
'"/>

Contact: Alicia Sokol
216-445-9661
JAMA and Archives Journals
9-Nov-2004

Page: 1 2
Related medicine news :

1. Calcium and vitamin D most effective for treatment of Crohns-related bone loss
2. Calcium boost to youths bones could reduce osteoporosis risk
3. Calcium-blocker drug slows artery clogging better than beta blocker
4. Calcium-dependent potassium channels as target to increase drug delivery to brain tumors
5. Calcium channel gene may play a role in severity of neurodegenerative brain disease
6. Calcium intake may be associated with reduced risk of colon cancer
7. This summer, Camp Calcium is where the boys are
8. American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)
9. Some brain cells change channels to fine-tune the message
10. Major new study finds long-acting calcium channel blockers inferior to other antihypertensive drugs
11. Researchers discover alcohol-sensitive membrane channel